“The expanded clearance will give spine surgeons access to a next generation bioactive bone graft product that can be used in challenging spine fusion surgery. The clearance will also allow us to greatly expand our growing distribution network and get the product into more surgeons’ hands,” said Synergy president and CEO Mark Borden, PhD.
BIOSPHERE PUTTY is the company’s that uses patented bioactive glass spheres. The product has the highest bioactive glass content on the market.
More Articles on Devices:
Biomet, Medtronic, Misonix & more – 7 Key Notes
RTI Surgical Unveils Precision Allograft Cartilage Kit
St. Jude Medical Pays $200M for NeuroTherm: 5 Facts on the Transaction
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
